Sunday, May 20, 2018 1:39:35 AM
ONCX in phase one, of FDA trials for Cancer treatment.
Early funding for this research came from the Susan G. Komen Foundation and the U.S. Government and Oncolix maintains their connection with MD Anderson Treatment Centers.
Oncolix as a private company rose over $15,000,000 through several rounds of private offerings that are only available to accredited investors, family trusts, endowments and institutional investors.
Oncoix officers have agreed to have roughly $1,300,000 in compensation deferred and have also agreed to lock up their shares along with their principal shareholder until late 2018.
Greenville Health System is the principal shareholder.
GHS is not-for-profit healthcare network serving the medical needs of their communities for over a century and currently has over 15,000 employees.
Current President of GHS is Spence M. Taylor MD, who is the custodian of ONCX shares on behalf of Greenville.
Accredited investors include the Texas Emerging Technology Fund and the Ernest Mario Family Trust among others.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
The biographies of Oncolix officers, Board of Directors and company advisors have been released to the public and are available on the company website.
The Oncolix Team.
Management
Board Members
Prolanta Inventor
Company Advisors
Oncolix has a worldwide patent portfolio that is also available to view on the Oncolix website.
Leveraging these worldwide patents, Oncolix could be in a position to realize substantial gains in revenue and market capitalization.
IMO and FWIW.
Early funding for this research came from the Susan G. Komen Foundation and the U.S. Government and Oncolix maintains their connection with MD Anderson Treatment Centers.
Oncolix as a private company rose over $15,000,000 through several rounds of private offerings that are only available to accredited investors, family trusts, endowments and institutional investors.
Oncoix officers have agreed to have roughly $1,300,000 in compensation deferred and have also agreed to lock up their shares along with their principal shareholder until late 2018.
Greenville Health System is the principal shareholder.
GHS is not-for-profit healthcare network serving the medical needs of their communities for over a century and currently has over 15,000 employees.
Current President of GHS is Spence M. Taylor MD, who is the custodian of ONCX shares on behalf of Greenville.
Accredited investors include the Texas Emerging Technology Fund and the Ernest Mario Family Trust among others.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
The biographies of Oncolix officers, Board of Directors and company advisors have been released to the public and are available on the company website.
The Oncolix Team.
Management
Board Members
Prolanta Inventor
Company Advisors
Oncolix has a worldwide patent portfolio that is also available to view on the Oncolix website.
Leveraging these worldwide patents, Oncolix could be in a position to realize substantial gains in revenue and market capitalization.
IMO and FWIW.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
